tegavivint
Showing 1 - 6 of 6
Advanced Hepatocellular Carcinoma Trial (Tegavivint, Pembrolizumab)
Not yet recruiting
- Advanced Hepatocellular Carcinoma
- Tegavivint
- Pembrolizumab
- (no location specified)
Mar 21, 2023
Recurrent Leukemia, Refractory Leukemia Trial in Houston (Decitabine, Tegavivint)
Recruiting
- Recurrent Leukemia
- Refractory Leukemia
- Decitabine
- Tegavivint
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Columbus
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +3 more
- Osimertinib
- Tegavivint
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Jul 14, 2022
Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- +8 more
- Biospecimen Collection
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 8, 2023
Desmoid Tumor Trial in Canada, United States (Tegavivint)
Completed
- Desmoid Tumor
- Tegavivint
-
Boston, Massachusetts
- +6 more
Jun 8, 2022
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)
Recruiting
- Colorectal Carcinoma
- +21 more
- Dual X-ray Absorptiometry
- +2 more
-
Birmingham, Alabama
- +18 more
Jan 30, 2023